- Home
- LSF vs PMVP Comparison
LSF vs PMVP Comparison
Compare LSF & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSF
- PMVP
- Stock Information
- Founded
- LSF 2015
- PMVP 2013
- Country
- LSF United States
- PMVP United States
- Employees
- LSF N/A
- PMVP N/A
- Industry
- LSF Packaged Foods
- PMVP Medicinal Chemicals and Botanical Products
- Sector
- LSF Consumer Staples
- PMVP Health Care
- Exchange
- LSF Nasdaq
- PMVP Nasdaq
- Market Cap
- LSF 71.7M
- PMVP 71.9M
- IPO Year
- LSF 2020
- PMVP 2020
- Fundamental
- Price
- LSF $6.01
- PMVP $1.09
- Analyst Decision
- LSF Strong Buy
- PMVP Strong Buy
- Analyst Count
- LSF 2
- PMVP 3
- Target Price
- LSF $7.75
- PMVP $5.33
- AVG Volume (30 Days)
- LSF 105.7K
- PMVP 99.9K
- Earning Date
- LSF 05-07-2025
- PMVP 03-03-2025
- Dividend Yield
- LSF N/A
- PMVP N/A
- EPS Growth
- LSF N/A
- PMVP N/A
- EPS
- LSF N/A
- PMVP N/A
- Revenue
- LSF $43,295,137.00
- PMVP N/A
- Revenue This Year
- LSF $22.58
- PMVP N/A
- Revenue Next Year
- LSF $20.06
- PMVP N/A
- P/E Ratio
- LSF N/A
- PMVP N/A
- Revenue Growth
- LSF 26.50
- PMVP N/A
- 52 Week Low
- LSF $1.90
- PMVP $1.02
- 52 Week High
- LSF $10.90
- PMVP $2.26
- Technical
- Relative Strength Index (RSI)
- LSF 47.74
- PMVP 25.04
- Support Level
- LSF $4.69
- PMVP $1.21
- Resistance Level
- LSF $7.35
- PMVP $1.30
- Average True Range (ATR)
- LSF 0.53
- PMVP 0.07
- MACD
- LSF 0.15
- PMVP -0.01
- Stochastic Oscillator
- LSF 49.62
- PMVP 25.00
About LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.